Abstract
Poly A:Poly U is a biological response modifier consisting of the twin-chain RNA polymers polyadenylic and polyuridylic acids forming a synthetic polyribonucleotide complex. The compound is endowed with a variety of immunopharmacological activities on both the humoral and cellular components of the immune response and exhibits antitumor effects. To date, Poly A:Poly U has been administered to over 1,000 individuals and proven to be remarkably safe. Its beneficial effect has been documented in patients with surgically treated breast cancer after its administration following radiotherapy, and in gastric cancer patients in conjunction with chemotherapy. This presentation will focus on reviewing the main immunological activities of Poly A:Poly U with a special emphasis on cytokine production and interaction.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ducret JP, Caille P, Sancho-Garnier H, Amiel JL, Michelson M, Hovanessian AG, Youn JK, Lacour F (1985) A phase I clinical tolerance study of polyadenylic-polyuridylic acid in cancer patients. J Biol Resp Modif 4: 129–33
Dy M, Schneider E, Arnould A (1990) Poly A:Poly U induces circulating colony simulating activity resulting from interactions between endogeneous interleukin-6 and serum components. Submitted
Han IH, Johnson AG (1976) Regulation of the immune system by synthetic polynucleotides. VI. Amplification of the immune response in young and aging mice. J Immunol 117: 423–7
Hovanessian AG, Riviere Y, Montagnier L, Michelson M, Lacour J, Lacour F (1982) Enhancement of interferon-mediated protein kinase in mouse and human plasma in response to treatment with polyadenylic-polyuridylic acid ( Poly A: Poly U). J Interferon Res. 2: 209–15
Hovanessian AG, Youn JK, Buffet-Janvresse C, Riviere Y, Michelson M, Lacour J, Lacour F (1985) Enhancement of natural killer cell activity and 2–5-A synthetase in operable breast cancer patients treated with polyadenylic-polyuridylic acid. Cancer 55: 357–62
Hovanessian A, Galabru J, Riviere Y, Montagnier L (1988) Efficiency of Poly A:Poly U as an adjuvant. Immunol today 9: 161–2
Johnson AG (1979) Modulation of the immune system by synthetic polynucleotides. Springer Semin Immunopathol 2: 149–68
Lacour J, Spira A, Petit JY, Sarrazin D, Lacour F, Michelson M, Delage G, Contesso G (1980) Adjuvant treatment with polyadenylicpolyuridylic acid (Poly A:Poly U) in operable breast cancer. Lancet ii: 161–4
Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D, Contesso G, Viguier J (1984) Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br Med J 288: 589–92
Lacour J, Lacour F, Ducot B, Spira A, Michelson M, Petit JY, Sarrazin D, Contesso G (1988) Polyadenylic-polyuridylic acid as adjuvant in the treatment of operable breast cancer: recent results. Europ J Surg Onc 14: 311–6
Lee BK, Yu YJ, Youn JK (1990) Effect of polyadenylic-polyuridylic acid on the proliferative responsiveness of mouse thymus and spleen cells. Yonsei Medical Journal, 31: 174–81
Metcalf D (1989) Actions and interactions of G-CSF, LIF and IL6 on normal and leukemic murine cells. Leukemia 3: 349
Michelson AM, Lacour F, Lacour J (1985) Mini review: polyadenylicpolyuridylic acid in the cotreatment of cancer (42055). Proc Soc Exp Biol Med 179: 1–8
Odean MJ, Frane CM, Van der Virren M, Tomai MA, Johnson AG (1990) Involvement of gamma interferon in antibody enhancement by adjuvants. Infect Imm 58: 427–32
Petrequin PR, Johnson AG (1984) Macrophage activation by adjuvants in aging mice. J Leucocyte Biology 35 (3): 251–63
Pignol B, Maisonnet T, Mencia-Huerta JM, Braquet P (1989) The double-stranded polynucleotide complex polyadenylate-polyuridylate (Poly A:Poly U) increases IL-6 production by fibroblasts. Presented at the 7th International Congress of Immunology, Berlin (West), July 30 - August 5, 1989, Abstract 57–63, p 319
Youn JK, Hovanessian AG, Riviere Y, Hue G, Lacour F (1983) Enhancement of natural killer cell activity and 2–5-A synthetase in mice treated with polyadenylic-polyuridylic acid. Cell Immunol 79: 298–308
Youn JK, Kim BS, Min JS, Lee KS, Choi HJ, Lee YB, Lee DW, Koh EH, Kim KW, Lee KB, Michelson AM (1987) Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapy agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity. Int J Immunopharmac, 9: 313–24
Youn JK, Kim BS, Min JS et al (1990) Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int J Immunopharmac 12: 289–95.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Tursz, T., Morin, A., Deschamps De Paillette, E., Johnson, A.G. (1990). Poly A-Poly U: An Updated Review. In: Masihi, K.N., Lange, W. (eds) Immunotherapeutic Prospects of Infectious Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76120-1_35
Download citation
DOI: https://doi.org/10.1007/978-3-642-76120-1_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76122-5
Online ISBN: 978-3-642-76120-1
eBook Packages: Springer Book Archive